Volume 21, Issue 4 (8-2018)
J Arak Uni Med Sci 2018, 21(4): 30-39 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Talebzadeh N, Ghorbian S. Evaluation of Promoter Methylation Pattern of the Vascular Endothelial Growth Factor (VEGF) Gene in Metabolic Syndrome Patients of East Azerbaijan Province. J Arak Uni Med Sci 2018; 21 (4) :30-39
URL: http://jams.arakmu.ac.ir/article-1-5578-en.html
URL: http://jams.arakmu.ac.ir/article-1-5578-en.html
1- Department of Molecular Genetics, Faculty of Basic Sciences, Ahar Branch, Islamic Azad University, Ahar, Iran.
2- Department of Molecular Genetics, Faculty of Basic Sciences, Ahar Branch, Islamic Azad University, Ahar, Iran. ,ghorbian20@yahoo.com
2- Department of Molecular Genetics, Faculty of Basic Sciences, Ahar Branch, Islamic Azad University, Ahar, Iran. ,
Abstract: (2901 Views)
Background and Aim: Metabolic syndrome (MS) was committed multiple disorders including diabetes, hypertension, and obesity, which were played influential effects on the mortality rates of patients suffering from of cardiovascular disorders. Vascular endothelial growth factor (VEGF) is a protein that stimulates vascular and angiogenesis. One of the most common epigenetic changes is methylation of the promoter regions of genes, which leads to the regulation of gene expression. We aimed to assess the methylation pattern of promoter regions of VEGF gene which may act a critical role in the pathogenesis of MS.
Materials and Methods: In this descriptive-analytical investigation, we have assessed a total of 100 subjects, which were included 50 of cases diagnosed as MS and 50 healthy individuals as a control group. Methyl specific polymerase chain reaction (MS–PCR) method was performed to analyzing of VEGF gene promoter methylatin patterns and data analysis was performed using Chi Square test and SPSS 23 software.
Findings: The frequencies of VEGF gene promoter methylation observed in 32% and 20% of case and control individuals, respectively. Our findings revealed that the frequencies of the gene methylated were not statistically different between two groups (p=0.239). In other hand, our findings revealed a statistically significant difference regarding to the clinical parametrics including, triglycired (p=0.050), cholesterol (p=0.046), suger blood (p=0.025) and HbA1C (p=0.016) between cases and control groups (p=0.05).
Conclusion: According to our findings, methylation alteration in VEGF gene did not show any critical role in the pathogenesis of MS and it is suggested that more evidence will be needed to approve the present results.
Materials and Methods: In this descriptive-analytical investigation, we have assessed a total of 100 subjects, which were included 50 of cases diagnosed as MS and 50 healthy individuals as a control group. Methyl specific polymerase chain reaction (MS–PCR) method was performed to analyzing of VEGF gene promoter methylatin patterns and data analysis was performed using Chi Square test and SPSS 23 software.
Findings: The frequencies of VEGF gene promoter methylation observed in 32% and 20% of case and control individuals, respectively. Our findings revealed that the frequencies of the gene methylated were not statistically different between two groups (p=0.239). In other hand, our findings revealed a statistically significant difference regarding to the clinical parametrics including, triglycired (p=0.050), cholesterol (p=0.046), suger blood (p=0.025) and HbA1C (p=0.016) between cases and control groups (p=0.05).
Conclusion: According to our findings, methylation alteration in VEGF gene did not show any critical role in the pathogenesis of MS and it is suggested that more evidence will be needed to approve the present results.
Type of Study: Original Atricle |
Subject:
Basic Sciences
Received: 2018/01/17 | Accepted: 2018/05/27
Received: 2018/01/17 | Accepted: 2018/05/27
References
1. AlSaraj F, McDermott JH, Cawood T, McAteer S, Ali M, Tormey W, Cockburn BN, Sreenan S. Prevalence of the metabolic syndrome in patients with diabetes mellitus. Irish journal of medical science. 2009; 178(3):309-13.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Jama. 2002; 287(3):356-9.
3. Gharipour M, Sarrafzadegan N, Sadeghi M, Khosravi A, Hoseini M, Khosravi-Boroujeni H, Khaledifar A. The metabolic syndrome and associated lifestyle factors among the Iranian population. Advanced biomedical research. 2015; (1):84.
4. Sarrafzadegan N, Kelishadi R, Baghaei A, Sadri GH, Malekafzali H, Mohammadifard N, Rabiei K, Bahonar A, Sadeghi M, O'Laughlin J. Metabolic syndrome: an emerging public health problem in Iranian women: Isfahan Healthy Heart Program. International journal of cardiology. 2008; 131(1):90-6.
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005; 112(17):2735-52.
6. Misra A, Chaudhary D, Vikram NK, Mittal V, Devi JR, Pandey RM, Khanna N, Sharma R, Peshin S. Insulin resistance and clustering of atherogenic risk factors in women belonging to low socio-economic strata in urban slums of North India. Diabetes research and clinical practice. 2002; 56(1):73-5.
7. Pacholczyk M, Ferenc T, Kowalski J. Metabolic syndrome. Part III: its prevention and therapeutic management. Postepy higieny i medycyny doswiadczalnej (Online). 2008; 62:559-70.
8. Deedwania P, Gupta R. Management issues in the metabolic syndrome. JAPI. 2006; 54:797-810.
9. Grundy SM. Metabolic syndrome: therapeutic considerations. InAtherosclerosis: Diet and Drugs 2005 (pp. 107-133). Springer, Berlin, Heidelberg.
10. Tavassoli AA, Gharipour M, Khosravi A, Kelishadi R, Siadat ZD, Bahonar A, Sadri GH, Sadeghi M, Rabiei K, Sajjadi F, Zarfeshani S. Gender differences in obesogenic behaviour, socioeconomic and metabolic factors in a population-based sample of Iranians: the IHHP study. Journal of health, population, and nutrition. 2010; 28(6):602.
11. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Current pharmaceutical design. 2004; 10(27):3331-48.
12. Bottardi S, Aumont A, Grosveld F, Milot E. Developmental stage–specific epigenetic control of human β-globin gene expression is potentiated in hematopoietic progenitor cells prior to their transcriptional activation. Blood. 2003; 102(12):3989-97.
13. Yara S, Lavoie JC, Levy E. Oxidative stress and DNA methylation regulation in the metabolic syndrome. Epigenomics. 2015; 7(2):283-300.
14. Kamboh MI, Crawford MH, Aston CE, Leonard WR. Population distributions of APOE, APOH, and APOA4 polymorphisms and their relationships with quantitative plasma lipid levels among the Evenki herders of Siberia. Human biology. 1996: 231-43.
15. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wägele B, Altmaier E, Deloukas P, Erdmann J, Grundberg E, Hammond CJ. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011; 477(7362):54.
16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids research. 1988; 16(3):1215.
17. Shiota K, Kogo Y, Ohgane J, Imamura T, Urano A, Nishino K, Tanaka S, Hattori N. Epigenetic marks by DNA methylation specific to stem, germ and somatic cells in mice. Genes to Cells. 2002; 7(9):961-9.
18. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature medicine. 2003; 9(6):669.
19. Amoli MM, Amiri P, Alborzi A, Larijani B, Saba S, Tavakkoly-Bazzaz J. VEGF gene mRNA expression in patients with coronary artery disease. Molecular biology reports. 2012; 39(9):8595-9.
20. Sundrani DP, Reddy US, Joshi AA, Mehendale SS, Chavan-Gautam PM, Hardikar AA, Chandak GR, Joshi SR. Differential placental methylation and expression of VEGF, FLT-1 and KDR genes in human term and preterm preeclampsia. Clinical epigenetics. 2013; 5(1):6.
21. Siddique AN, Nunna S, Rajavelu A, Zhang Y, Jurkowska RZ, Reinhardt R, Rots MG, Ragozin S, Jurkowski TP, Jeltsch A. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a–Dnmt3L single-chain fusion protein with increased DNA methylation activity. Journal of molecular biology. 2013; 425(3):479-91.
22. Fielder W, Graeven U, Ergün S, Verago S, Kilic N, Stockschläder M, Hossfeld DK. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia. 1997; 11(8):1234.
23. Sánchez I, Reynoso-Camacho R, Salgado LM. The diet-induced metabolic syndrome is accompanied by whole-genome epigenetic changes. Genes & nutrition. 2015; 10(4):21.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
